INTRODUCTION
============

The gastrointestinal tract mucosa constantly confronts a variety of potentially injurious agents involving pathogenic bacteria, normal bacterial floras, and even toxic dietary factors, which usually cause infection and inflammation and have been implicated in essential barrier function failure including inflammatory bowel disease ([@b14-ajas-29-1-134]). Nutritional modulation offers an appropriate approach to prevent mucosal barrier injury.

Herbal ingredients are deemed significant nutrients to improve animal health in China. *Acanthopanax senticosus* (AS) is a well-known shrub native to far eastern areas of Russia and the northern regions of Japan, Korea, and China ([@b4-ajas-29-1-134]). Polysaccharides (ASPS) are a major active ingredient of the aqueous extract isolated from AS. Our previous research revealed that the anti-inflammatory role was closely linked to down-regulatory expression of pro-inflammatory cytokines ([@b9-ajas-29-1-134]). Due to inflammatory intestinal condition resulting in compromised intestinal barrier function preliminary research was conducted to determine the effect of ASPS on intestinal function. From this, we hypothesized that ASPS would sustain positive changes during intestinal mucosal damage during inflammation conditions.

In the present study, we employed a well-documented intestinal injury model in the mouse by injecting *Escherichia coli* lipopolysaccharide (LPS) to assess the effect of ASPS on intestinal morphology, gut digestive profile, intestinal tight junction proteins, and mucous layer secretions that characterize intestinal mucosal barrier function, and to probe into the potential mechanisms by which ASPS protects the intestinal mucosal against injurious agents.

MATERIALS AND METHODS
=====================

*Acanthopanax senticosus* polysaccharide preparation
----------------------------------------------------

ASPS were prepared from the root of *Acanthopanax senticosus* using Ethanol precipitation method as previously described ([@b9-ajas-29-1-134]). Protein was removed by Sevag method ([@b27-ajas-29-1-134]) and the polysaccharide content at post-purification was 92.7% as determined by the phenol sulfuric acid method ([@b6-ajas-29-1-134]). Monosaccharide composition analysis of ASPS by ion chromatography according to the method of [@b22-ajas-29-1-134] showed that it was a type of heteropolysaccharide composed of glucose, galactose, arabinose, mannose, rhamnose, and xylopyranose.

Mice care and experimental design
---------------------------------

All studies were approved by and performed in compliance with the guidelines of the Animal Care and Use Committee of Liaoning Province, China. Male Kunming mice with SPF grade at 5 wk of age (Changsheng Life Sciences Co. Ltd., Changchun Jilin, China) were kept under stable temperature (21°C±1°C) and humidity (45%±2%) with a 12-h-light/dark cycle and free access to food and water. Following the adaption to the housing condition for 1 wk, mice were distributed into random groups of 6 mice (3 mice/cage) and treated as follows: mice were given ASPS aqueous solution at 300 mg/kg body weight (BW) by daily oral gavage for continuous 14 days (ASPS+LPS group), the others were given an equivalent amount of sterile saline (Control group) and (LPS group). On the morning of 15 days, mice in LPS group and ASPS+LPS group were injected intraperitoneally with *Escherichia coli* LPS (*E. coli* Serotype 055: B5, Sigma, Saint Louis, MO, USA) at 4 mg/kg BW, and others in Control group were given an equivalent amount of sterile saline. ASPS dose was determined in accordance with optimal dose obtained in piglets of our previous study ([@b9-ajas-29-1-134]), by using dose conversion formula for different animals in pharmacological studies ([@b31-ajas-29-1-134]).

Intestinal sample collections
-----------------------------

Following 4 h post-injection with LPS or saline, all the mice were killed by cervical dislocation. Intestinal segments measuring 1 cm and 10 cm in length were excised respectively from the proximal jejunum in each mouse. The 1-cm intestinal segments were washed with ice-cold phosphate-buffered saline (PBS) and the liquid removed with filter paper, and then fixed in 10% formaldehyde for histology sections to observe intestinal morphology. The 10-cm intestinal segments were opened longitudinally and flushed with ice-cold PBS and scraped to gather mucosa samples, which were rapidly freeze-clamped in liquid nitrogen and then stored at --80°C.

Intestinal morphology
---------------------

Tissue slices were prepared by hematoxylin and eosin straining according to the method of [@b20-ajas-29-1-134]. In brief, intestinal segments were processed by being fixed, dehydrated, paraffined, embedded, sliced and stained. Five observations were made on each slice and in each observation two villi that were well-stretched and parallel were measured quantitatively for analysis of villus height (the vertical distance from intestinal gland to the villus tip), crypt depth (the vertical distance from the opening of intestinal gland to the bottom), and villus height:crypt depth ratio (VCR).

Intestinal mucosa cells count
-----------------------------

Intraepithelial goblet cells and lymphocytes were assayed by hematoxylin and eosin straining. Tissue slices were prepared according to the method of [@b20-ajas-29-1-134]. In brief, intestinal segments were processed by fixed, dehydrated, paraffined, embedded, sliced and stained. Lymphocytes near the side of the intestinal epithelial cells (IEC) base membrane were characterized as small cells with hyperchromatic large nucleus. Goblet cells located between IEC were characterized by relative large cell with hyperchromatic small nucleus. These two kinds of intestinal mucosa cells were observed among one hundred IEC of the third pair of well-stretched and parallel villi in each of the five observation fields of a Axio Scope A1 of ZEISS biomicroscope (Oberkochen, German)

Determination of biochemical parameters of intestinal mucosa
------------------------------------------------------------

Mucosal disaccharidase activity including lactase, sucrase, and maltase were measured by glucose oxidase-peroxidase conjugated method according to [@b13-ajas-29-1-134] using commercial kit (Nanjing Jiancheng Biological Product, Nanjing, China), and the values of enzyme activity are expressed as U/mg protein. The activity of diamine oxidase (DAO), as well as the concentration of tumor necrosis factor (TNF)-α and intestinal trefoil peptide (ITP) were analyzed using enzyme-linked immunosorbent assay with commercial kits (R&D Inc., Los Angeles, CA, USA).

Real-time polymerase chain reaction detection
---------------------------------------------

In brief, total RNA was extracted from intestinal mucosa using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The quantity and quality of the RNA were verified by spectrophotometry (UV-300; Applied Photophysics, Manchester, England) and agarose electrophoresis. cDNA synthesis was performed using a Promega GoScript reverse transcription system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Gene-specific primers for *β-*actin (forward: 5′-TCCCTGTATGCCTCTGGT-3′; reverse: 5′-TGTCACGCACGATTTCC-3′; GenBank No: NM_007393), heat shock protein (HSP70) (forward: 5′-CACAAGAAGG ACATCAGCCAGAA-3′; reverse: 5′-GGAACAGGTCCG AGCACAGC-3′; GenBank No: NM_010478); epidermal growth factor (EGF) (forward: 5′-CCCTCGTCA CTGGTTGT -3′; reverse: 5′- TTCTGTCCCATCATCGTC -3′; GenBank No: NM_010113); epidermal growth factor receptor (EGFR) (forward: 5′- AATCCCTTTGGAGAA CCT -3′; reverse: 5′- TGAATCGCACAGCACC -3′; GenBank No: NM_007912) were synthesized by Dingguo Changsheng Biotech Co. (Beijing, China). The polymerase chain reaction (PCR) quantitative analysis was carried out on PCR system (T300, Biometra, Jena, Germany) and performed in a 20 *u*L reaction system containing 7 μL nuclease-free water, 0.4 μL up-premier (10 μmol/L) and 0.4μL down-premier (10 μmol/L), 10.0 μL qPCR master mix (2×). The PCR cycling conditions were a pre-denaturation cycle at 95°C for 10 min firstly, followed by 40 cycles at 95°C for 15 s and 60°C for 60 s, then 1 cycle at 95°C for 15 s, 60°C for 60 min and 95°C for 15 s. The relative expression of target genes relative to *β*-actin was calculated by using the 2^−ΔΔCT^ method ([@b18-ajas-29-1-134]).

Western blot for protein expression analysis
--------------------------------------------

In brief, intestinal mucosal samples were homogenized in 1 mL lysis buffer and centrifuged at 12,000×*g* at 4°C for 30 min for supernatants collection, and then the protein concentrations were measured using phenol reagent method. An equal amount of proteins samples (20 to 40 μg) was separated on a 10% or 12% reducing polyacrylamide gel and transferred onto polyvinylidene difluoride membranes, and incubated with primary antibodies. Immunoblots were blocked with 3% bull serum albumin (BSA) in Tris-buffered saline for 70 min at room temperature and incubated overnight at 4°C with the specific primary antibodies in Tris-buffered saline and 0.05% Tween 20 containing 1% BSA. The specific primary antibody included rabbit anti-claudin-1 (1:1,000; Proteintech, Chicago, IL, USA) and anti-occludin-1 (1:1,000; Proteintech, USA). Blots were washed with the same buffer and then incubated with anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5,000; Proteintech, USA) for 120 min at room temperature. Membranes were washed in the same buffer and antigen-antibody complexes visualized by using an ECL kit (Pierce, Waltham, MA, USA). The density of the bands was quantified using the Image J 1.46r analysis software.

Statistical analyses
--------------------

Individual mouse was used as experimental unit for analysis of experimental indices. Data were analyzed by one-way analysis of variance. Differences between the groups were analyzed by Duncan multiple comparisons Tests. The results were expressed as means±standard error of mean (SEM), and a 5% level of probability was considered significant for all analyses. The statistical calculations were carried out by using SPSS 19.0 software (Cabit Co., LTD, Shanghai, China).

RESULTS
=======

Intestinal morphology and mucosal cell count
--------------------------------------------

The mice in LPS group had significantly lowered villus height (24.55% lower, p\<0.05) and VCR (38.78% lower, p\<0.05), as well as greater crypt depth (21.69% greater, p\<0.05) in jejunum compared with the mice in control group ([Figure 1](#f1-ajas-29-1-134){ref-type="fig"}; [Table 1](#t1-ajas-29-1-134){ref-type="table"}). Correspondingly, ASPS+LPS group significantly increased the villus height (20.84% higher, p\<0.05) and VCR (42% higher, p\<0.05), as well as decreased the crypt depth (15.55% lower, p\<0.05) compared with the LPS group. Intestinal goblet cells number in LPS group was not significantly different from the mice in control group ([Figure 2](#f2-ajas-29-1-134){ref-type="fig"}). The mice in ASPS+LPS group showed significantly increased goblet cells (24.89% higher, p\<0.05) relative to those in LPS group. Intraepithelial lymphocytes were not significant different among different groups (p\>0.05).

Proteins expression of intestinal tight junction
------------------------------------------------

Mucosal Occludin-1 proteins expression was significantly lower (53.33% lower, p\<0.05) in LPS group compared with control group although intestinal claudin-1 protein expression did not differ between the two groups (p\>0.05) ([Figure 3](#f3-ajas-29-1-134){ref-type="fig"}; [Table 2](#t2-ajas-29-1-134){ref-type="table"}). Correspondingly, the mice in ASPS+LPS group demonstrated significant increase in intestinal occludin-1 (71.43%, p\<0.05) proteins expression compared with those in LPS group. ASPS pre-treatment had no effect on intestinal claudin-1 protein expression.

Mucosal disaccharidase activity and other biochemical parameters
----------------------------------------------------------------

The mice in LPS group had significantly lower lactase (20% lower, p\<0.05) and sucrase (50% lower, p\<0.05) activities compared to the mice in control group ([Table 3](#t3-ajas-29-1-134){ref-type="table"}). Compared to the LPS mice without ASPS treatment, the mice in ASPS+LPS group had significant higher lactase activity (45% higher, p\<0.05). However, jejunal sucrase and maltase activities were not different (p\>0.05) among different groups. The mice in LPS group exhibited lower level of DAO and ITP as well as higher TNF-α than did the Control groups ([Table 3](#t3-ajas-29-1-134){ref-type="table"}). Correspondingly, significantly improved DAO activity (61.48% higher, p\<0.05) and ITP (17.75% higher, p\<0.05) as well as reduced concentration of TNF-α (22.28% lower, p\<0.05) were observed compared with those in LPS group. There were no differences on these indices between control and ASPS+LPS group (p\>0.05).

Intestinal HSP70, EGF, and EGFR mRNA expression
-----------------------------------------------

The mice in LPS group displayed significantly lower *EGF* and *EGFR* gene mRNA expression as well as increased HSP70 gene expression in intestinal mucosa compared to those in control group ([Table 4](#t4-ajas-29-1-134){ref-type="table"}). In contrast to those in LPS group, the mice treated with ASPS had significantly raised mRNA expression of *EGF* (100% higher, p\<0.05) and *EGFR* (200% higher, p\<0.05) gene, and reduced the *HSP70* (77.42% lower, p\<0.05) gene expression. There were no differences on these indices between control and ASPS+LPS group (p\>0.05).

DISCUSSION
==========

ASPS has demonstrated its immune-regulatory and inhibitory inflammatory activity in animal models and clinical trials in many studies ([@b7-ajas-29-1-134]; [@b33-ajas-29-1-134]; [@b28-ajas-29-1-134]; [@b10-ajas-29-1-134]; [@b3-ajas-29-1-134]; [@b9-ajas-29-1-134]). However, focusing on the gastrointestinal tract mucosa constantly being confronted with a variety of potentially injurious agents, few researches were conducted to determine the role of pre-treatment with ASPS on the intestinal mucosal barrier under inflammatory conditions.

In the current study, to evaluate whether ASPS pre-treatment could attenuate the damage to intestinal mucosal function in a challenged animal, we employed a well-documented model of mucosal impairment in mice built by administrating *Escherichia coli* LPS. This toxin molecule is present on the membrane of gram-negative bacteria and causes acute systemic inflammatory symptoms characterized by transient fever, anorexia, somnolence and inactivity ([@b26-ajas-29-1-134]), as well as intestinal morphologic alterations. Exposure to LPS further results in dysfunction of intestinal mucosa including negative alternations in digestive function, mucosal integrity and immune function ([@b15-ajas-29-1-134]), and has been frequently applied in many researches for studying nutrition and gastrointestinal physiology ([@b17-ajas-29-1-134]; [@b12-ajas-29-1-134]; [@b16-ajas-29-1-134]). In addition, the time point of sampling in the present experiment was chosen at 4 h post-injection with LPS as previous studies suggest that the acute intestinal inflammatory response occurs 3 to 6 h following LPS injection ([@b21-ajas-29-1-134]; [@b17-ajas-29-1-134]; [@b16-ajas-29-1-134]).

Intestinal epithelial barrier consists of the intestinal morphology, which includes a tight junction (TJ) between epithelial cells, mucus layer overlying the mucous epithelium, various digestive enzymes that simultaneously affects biological and immunological barriers and plays vital role in protecting gut against a variety of injurious agents. Villus height, crypt depth, as well as VCR are the critical factors of the intestinal epithelial barrier and vital to the full digestion and absorption of nutrients ([@b25-ajas-29-1-134]). Of them, enhanced villus height and VCR present absorption ability improvement through increased contact area, and decreased crypt depth reflects the elevated proliferation rate of IEC. Our present study demonstrated intestinal morphology damage at 4 h following LPS challenge. As expected, ASPS treatment resulted in the alleviation of intestinal morphology damage induced by LPS challenge which suggests potently that ASPS might improve intestinal nutrients absorption ability, and the reason may be partially do with the capacity of ASPS to sustain growth and differentiation of epithelial cells. However, the underlying mechanism needs further research.

The complete TJ between IEC is a vital structural foundation of the intestinal mucosal epithelial barrier ([@b29-ajas-29-1-134]). In agreement with many researches demonstrating LPS-induced inflammation results in expression alterations of TJ proteins ([@b30-ajas-29-1-134]; [@b16-ajas-29-1-134]), our study found that occludin-1 protein expression was reduced by LPS challenge and ASPS facilitated its protein expression to nearly restore it to control level. Therefore, our finding concerning improved intestinal occludin-1 protein expression suggests that ASPS can be a preventive nutrient to lessen the loss of the epithelial barrier suffering from inflammatory challenge.

Disaccharidases including lactase, sucrase, and maltase overlying the mucosal surface play a vital part in decomposing disaccharides and facilitating mucosa maturation and gut digestive function ([@b19-ajas-29-1-134]). In the present study, ASPS increased intestinal lactase activity in challenged mice, which indicates that ASPS protected the intestinal digestive function from damage. [@b34-ajas-29-1-134] has reported that insulin can promote mucosa maturation, and increase mucosal disaccharidase activities in neonatal pigs. Interestingly, although not direct observation of insulin level, based on our previous research demonstrating that ASPS can induce the increase in growth hormone, insulin-like growth factor I and decrease glucose in LPS-challenged weaned piglets ([@b9-ajas-29-1-134]), we can infer an increase in insulin concentration was induced by ASPS. Therefore, it is possible that ASPS supplementation attenuated the decrease in disaccharidase activity partially by stimulating insulin release.

DAO as intracellular enzyme with high activity exists in the intestinal villous cells and its activity declines when IEC is injured. Thus, the DAO activity of intestinal mucosa can reflect the changes in intestinal mucosa integrity, permeability and the barrier function ([@b32-ajas-29-1-134]). In the current study, our findings concerning oral ASPS alleviated the loss of DAO activity further prove the intestinal mucosal function is boosted with the treatment of ASPS under the condition of challenge.

The modulation of mucosal inflammatory response by ASPS was assessed under inflammatory intestinal conditions resulting in compromised barrier function ([@b14-ajas-29-1-134]). Over-release of TNF-α to the mucosa induced by LPS is primarily responsible for the disruptive intestinal mucosal function ([@b24-ajas-29-1-134]; [@b8-ajas-29-1-134]). Similar to TNF-α, a high level of HSP70 is also indicative to inflammatory response in the intestine. Consistent with our previous study demonstrating the relief of inflammatory response by ASPS via modulating the release of pro-inflammatory cytokines including TNF-α, interleukin (IL)-1β, and IL-6 in the blood of piglets ([@b9-ajas-29-1-134]), our current determination of inflammatory mediators showed that ASPS decreased the intestinal mucosal concentration of TNF-α and HSP70, which further support the above results concerning an improved intestinal mucosal barrier by ASPS.

It is apparent that the intestinal mucosal barrier is dependent on the presence of a monolayer of epithelial cells joined by TJ, which form a cellular barrier to many of the wide range of potential injuries. Although intestinal epithelium represents the cellular frontier of the mucosa, it has long been recognized that the apical surface of this population is covered by a viscoelastic coat including large amounts of trefoil peptides selectively secreted by goblet cells ([@b24-ajas-29-1-134]), which are in conjunction with mucin glycoproteins to form a continuous gel on the luminal surface to prevent intestinal barrier damage ([@b11-ajas-29-1-134]). Previous studies revealed the ability of ITP in facilitating restitution of wounded mucosa and protecting the integrity of model intestinal epithelial monolayers against a variety of injurious agents ([@b5-ajas-29-1-134]). In our current study, relative to lower number of goblet cells and ITP concentration in challenged mice, the mice in ASPS groups presented a higher number of goblet cells and concentration of ITP even when compared with control group, which may be due to the capacity of ASPS functioning under both challenged and normal conditions as reported in our previous study ([@b9-ajas-29-1-134]). This observation also elucidates the distinct protective role of ASPS against injurious agents via promoting the formation of viscoelastic gel overlying the mucosa by the secreted products of the goblet cell population. However, the underlying mechanism needs further research.

EGF and its receptor EGFR are implicated by many studies ([@b2-ajas-29-1-134]; [@b25-ajas-29-1-134]) in the regulation of intestinal epithelium growth and differentiation, which are required for normal gut development and repair of intestinal mucosal injury ([@b1-ajas-29-1-134]). In the current study, these two indicators were examined to seek to further clarify the mechanism by which ASPS protect against mucosal barrier loss. EGF combination with its receptor EGFR conducts its stimulation signal intracellularly and can launch a series of cascade reaction through signaling pathways, where they act on transcription factors to modulate various physiological process ([@b23-ajas-29-1-134]). As expected, the sharply down-regulated EGF and EGFR mRNA expression following LPS challenge indicate the presence of intestinal epithelial damage. However, for the mice given LPS, the findings of ASPS pre-treatment elevating mRNA expression of EGF and EGFR suggest that ASPS contributes to proliferation and differentiation of the IEC to a certain extent, which coincided with the positive alteration in intestinal morphology, TJ, and mucus layer. Especially, our finding that an increased spectrum of EGFR superior to those of EGF was observed, this may involve various growth factors participating in the mucosal developmental process where these growth factors compete to combine with EGFR and lead to increased need of EGFR. These results propose that improvement in intestinal epithelium growth and differentiation may be the mechanism by which intestinal mucosal barrier damage is ameliorated by ASPS.

IMPLICATIONS
============

The present study demonstrates that oral pre-treatment of ASPS could mitigate intestinal mucosal barrier loss under challenged conditions by modulating the mRNA expression of EGF and EGFR. These results suggest that improvement in intestinal epithelium growth and differentiation may be the mechanism by which damage to the intestinal mucosal barrier by challenging agents is ameliorated by ASPS.
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![Intestinal morphology of mice in different groups (H&E staining). (a), (b), and (c) are the representative jejunal morphology images of in control, LPS and ASPS+LPS groups respectively. LPS, lipopolysaccharide; ASPS, *Acanthopanax senticosus* polysac polysaccharides from *Acanthopanax senticosus*.](ajas-29-1-134f1){#f1-ajas-29-1-134}

![Goblet cells and intraepithelial lymphocytes of intestinal mucosal in different groups (H&E staining, ×200). (a), (b), and (c) are representative jejunal goblet cells images in control, LPS and ASPS+LPS groups respectively. (d), (e), and (f) are representative jejunal intraepithelial lymphocytes images in control, LPS and ASPS+LPS groups respectively. LPS, lipopolysaccharide; ASPS, polysaccharides from *Acanthopanax senticosus*.](ajas-29-1-134f2){#f2-ajas-29-1-134}

![Effects of polysaccharides from *Acanthopanax senticosus* (ASPS) on protein expression of occludin-1 and claudin-1 challenged mice. The bands represent Western blot images of *β*-actin (a), occludin-1 (b), and claudin-1 (c) in jejunum. Column control, mice administrated by saline and injected with saline; Column LPS, mice administrated by saline and injected with LPS; Column ASPS+LPS, mice administrated by ASPS and injected with LPS. LPS, lipopolysaccharide.](ajas-29-1-134f3){#f3-ajas-29-1-134}

###### 

Effects of ASPS on intestinal morphology and mucosal cells count in LPS challenged mice[1](#tfn2-ajas-29-1-134){ref-type="table-fn"}

  Items                                                      Control                                                       LPS                                                           LPS+ASPS                                                     p-value
  ---------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------ ---------
  Villus height, μm                                          241.67 ± 13.95[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}   182.33 ± 15.77[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}   220.33 ± 5.41[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}   0.014
  Crypt depth, μm                                            102.17 ± 7.24[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}    124.33 ± 5.22[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}    105.00 ± 5.73[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}   0.044
  VCR                                                        2.45 ± 0.25[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}      1.50 ± 0.18[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}      2.13 ± 0.13[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}     0.011
  Goblet cells number/100 villous epithelium cells           700 ± 0.44[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}       6.67 ± 0.56[b](#tfn3-ajas-29-1-134){ref-type="table-fn"}      8.33 ± 0.21[a](#tfn3-ajas-29-1-134){ref-type="table-fn"}     0.036
  Intraepithelial lymphocytes/100 villous epithelium cells   69.33 ± 4.45                                                  85.33 ± 9.97                                                  76 ± 7.44                                                    0.123

ASPS, polysaccharides from *Acanthopanax senticosus*; LPS, lipopolysaccharide. VCR, villus height:crypt depth ratio.

Values are means±standard error of the mean of 6 mice per group.

Different superscript in a row indicates significant difference at p\<0.05.

###### 

Effects of ASPS on protein expression of intestinal tight junction proteins in LPS challenged mice[1](#tfn5-ajas-29-1-134){ref-type="table-fn"}

  Items                  Control                                                    LPS                                                         LPS+ASPS                                                   p-value
  ---------------------- ---------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------- ---------
  Claudin-1/*β*-actin    0.087 ± 0.003                                              0.080 ± 0.007                                               0.073 ± 0.003                                              0.153
  Occludin-1/*β*-actin   0.15 ± 0.03[a](#tfn6-ajas-29-1-134){ref-type="table-fn"}   0.07 ± 0.007[b](#tfn6-ajas-29-1-134){ref-type="table-fn"}   0.12 ± 0.01[a](#tfn6-ajas-29-1-134){ref-type="table-fn"}   0.006

ASPS, polysaccharides from *Acanthopanax senticosus*; LPS, lipopolysaccharide.

Values are means±standard error of the mean of 6 mice per group.

Different superscript in a row indicates significant difference at p\<0.05.

###### 

Effects of ASPS on disaccharidase activity and parameters of mucosa in LPS challenged mice[1](#tfn8-ajas-29-1-134){ref-type="table-fn"}

  Item                     Control                                                       LPS                                                         LPS+ASPS                                                     p-value
  ------------------------ ------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------ ---------
  Lactase (U/mg protein)   2.00 ± 0.09[b](#tfn9-ajas-29-1-134){ref-type="table-fn"}      1.60 ± 0.07[c](#tfn9-ajas-29-1-134){ref-type="table-fn"}    2.32 ± 0.11[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}     \<0.001
  Sucrase (U/mg protein)   0.36 ± 0.03                                                   0.25 ± 0.06                                                 0.37 ± 0.05                                                  0.108
  Maltase (U/mg protein)   0.18 ± 0.01                                                   0.22 ± 0.02                                                 0.14 ± 0.03                                                  0.06
  TNF-α (pg/mL)            365 ± 38.40[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}      534 ± 32.89[b](#tfn9-ajas-29-1-134){ref-type="table-fn"}    415 ± 38.07[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}     0.015
  ITP (ng/mL)              8.87 ± 0.28[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}      7.55 ± 0.53[b](#tfn9-ajas-29-1-134){ref-type="table-fn"}    8.89 ± 0.22[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}     0.033
  DAO (U/kg)               102.04 ± 11.59[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}   54.49 ± 7.70[b](#tfn9-ajas-29-1-134){ref-type="table-fn"}   87.99 ± 13.27[a](#tfn9-ajas-29-1-134){ref-type="table-fn"}   0.024

ASPS, polysaccharides from *Acanthopanax senticosus*; LPS, lipopolysaccharide. TNF-α, tumor necrosis factor-α; ITP, intestinal trefoil peptide; DAO, diamine oxidase.

Values are means±standard error of the mean of 6 mice per group.

Different superscript in a row indicates significant difference at p\<0.05.

###### 

Effects of polysaccharides from *Acanthopanax senticosus* (ASPS) on HSP70, EGF and its receptor EGFR mRNA expression of intestinal mucosal in LPS challenged mice[1](#tfn11-ajas-29-1-134){ref-type="table-fn"}

  Items   Control                                                        LPS                                                            LPS+ASPS                                                       p-value
  ------- -------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ---------
  HSP70   0.34 ± 0.04[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}      0.93 ± 0.26[b](#tfn12-ajas-29-1-134){ref-type="table-fn"}      0.21 ± 0.02[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}      0.011
  EGF     0.003 ± 0.0006[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}   0.001 ± 0.0003[b](#tfn12-ajas-29-1-134){ref-type="table-fn"}   0.003 ± 0.0003[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}   0.016
  EGFR    0.016 ± 0.002[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}    0.006 ± 0.002[b](#tfn12-ajas-29-1-134){ref-type="table-fn"}    0.012 ± 0.004[a](#tfn12-ajas-29-1-134){ref-type="table-fn"}    0.005

ASPS, polysaccharides from *Acanthopanax senticosus*; LPS, lipopolysaccharide; HSP70, heat shock protein 70; EGF, pidermal growth factor; EGFR, epidermal growth factor receptor.

Values are means±standard error of the mean of 6 mice per group.

Different superscript in a row indicates significant difference at p\<0.05.
